Key Highlights
- ARS Pharmaceuticals (NASDAQ:SPRY) was trading down 7.62% at USD 3.41 on Thursday, November 19, 2026, in intraday market data, which implies a prior close near USD 3.69 (calculated).
- Third-quarter Revenue was USD 37.7 million against USD 32.5 million a year earlier, while U.S. net product revenue from neffy reached USD 33.4 million versus USD 31.3 million.
- The net loss narrowed to USD 35.6 million, or USD 0.36 a share, from USD 51.2 million, or USD 0.52, as selling costs fell to USD 43.5 million from USD 74.8 million.
- Cash and short-term investments stood at USD 138.4 million on September 30, 2026, compared with about USD 245.0 million at December 31, 2025, and management targets Cash Flow breakeven by year-end 2027.
No Company Announcement Explains the Drop
ARS Pharmaceuticals (NASDAQ:SPRY) was trading at USD 3.41, down 7.62%, on November 19, 2026. No company announcement, filing or analyst action dated November 17 to November 19 was found to explain the move, and no reason is invented here. The latest hard news is the third-quarter report issued on November 5, 2026. The company sells neffy, a needle-free epinephrine nasal spray for severe allergic reactions including anaphylaxis, and it is still early in the commercial launch. A low-priced healthcare share can slide on thin Volume or profit-taking without any new disclosure, so the move alone says little about the underlying Business or its sales trend.
Neffy Revenue Growth Trails Rising Prescriber Demand
U.S. net product revenue from neffy rose from USD 31.3 million to USD 33.4 million, an increase of about 6.7% (calculated). Management said end-user Demand grew faster, which it linked to inventory swings in the channel. Total revenue also included USD 2.6 million of Supply revenue and USD 1.7 million of collaboration revenue. Published coverage noted that commercial coverage slipped to over 80% of lives and that revenue fell short of what the market had expected, though that coverage is a single report. Selling, general and administrative costs dropped after the company ended linear television and broad consumer advertising. Research and Development rose to USD 18.3 million because of a one-time USD 12.5 million license payment.
Cash Runway, Debt and the Next Data Readout
Cash and short-term investments were USD 138.4 million, made up of USD 25.6 million of cash and USD 112.7 million of short-term investments. Spending is guided to USD 114 million to USD 126 million of combined selling, administrative and research costs for the second half of 2026, including stock-based pay. Published coverage put term-loan debt near USD 121.8 million, a figure not confirmed here. The company had 100,248,400 shares outstanding on September 30, 2026. The next catalyst is interim Phase 2b data for ARS-2 in chronic spontaneous urticaria, expected in the first quarter of 2027, and any shortfall against the breakeven goal would raise financing risk.
Where Things Stand
The 7.62% slide has no announced company cause. ARS Pharmaceuticals (NASDAQ:SPRY) last reported on November 5, 2026, when revenue grew and the loss narrowed, yet neffy sales still lagged demand and cash fell by roughly USD 107 million since December 31, 2025 (calculated). With a sub-USD 5 share, a small number of trades can move the price and quoted moves can reverse. Investors will watch fourth-quarter neffy revenue, insurance coverage updates, the spending range and the ARS-2 readout in early 2027.






Please wait processing your request...